Sage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on an upgraded clinical trial last summer.
SAGE Therapeutics,?located in Cambridge, Massachusetts, has?submitted?a New Drug Application (NDA) to the?U.S.?Food and Drug Administration (FDA)?for brexanolone (SAGE-547) to treat postpartum depression (PPD).